Recent progresses in exosome-based systems for targeted drug delivery to the brain
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bashyal, Santosh | - |
dc.contributor.author | Thapa, Chhitij | - |
dc.contributor.author | Lee, Sangkil | - |
dc.date.accessioned | 2024-01-08T06:57:34Z | - |
dc.date.available | 2024-01-08T06:57:34Z | - |
dc.date.issued | 2022-08 | - |
dc.identifier.issn | 0168-3659 | - |
dc.identifier.issn | 1873-4995 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/69406 | - |
dc.description.abstract | Despite the multiple ongoing and novel initiatives for developing brain-targeted drug delivery systems, insurmountable obstacles remain. A perfect drug delivery device that can bypass the brain–blood barrier and boost therapeutic efficacy is urgently needed for clinical applications. Exosomes hold unrivaled benefits as a drug delivery vehicle for treating brain diseases due to their endogenous and innate attributes. Unique properties, such as the ability to penetrate physical barriers, biocompatibility, innate targeting features, ability to leverage natural intracellular trafficking pathways, favored tumor homing, and stability, make exosomes suitable for brain-targeted drug delivery. Herein, we provide an overview of recent exosome-based drug delivery nanoplatforms and discuss how these inherent vesicles can be used to deliver therapeutic agents to the brain to cure neurodegenerative diseases, brain tumors, and other brain disorders. Moreover, we review the current roadblocks associated with exosomes and other brain-targeted drug delivery systems and discuss future directions for achieving successful therapy outcomes. © 2022 Elsevier B.V. | - |
dc.format.extent | 22 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier B.V. | - |
dc.title | Recent progresses in exosome-based systems for targeted drug delivery to the brain | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.jconrel.2022.06.011 | - |
dc.identifier.bibliographicCitation | Journal of Controlled Release, v.348, pp 723 - 744 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85132700166 | - |
dc.citation.endPage | 744 | - |
dc.citation.startPage | 723 | - |
dc.citation.title | Journal of Controlled Release | - |
dc.citation.volume | 348 | - |
dc.type.docType | Review | - |
dc.publisher.location | 네델란드 | - |
dc.subject.keywordAuthor | Brain cancers | - |
dc.subject.keywordAuthor | Brain diseases | - |
dc.subject.keywordAuthor | Brain drug delivery systems | - |
dc.subject.keywordAuthor | Exosomes | - |
dc.subject.keywordAuthor | Neurodegenerative diseases | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.